SpringWorks Therapeutics Inc. (SWTX) – Company Press Releases
-
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
-
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
-
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
-
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
-
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
-
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
-
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
-
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
-
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
-
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
-
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
-
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
-
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
-
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
-
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
-
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
-
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
-
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
-
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
-
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
-
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
-
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
-
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
-
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
-
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
-
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
-
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
-
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
-
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
-
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
Back to SWTX Stock Lookup
